For people needing more satiety or muscle support, the Gladiator GLP-1 stands out because of its higher protein content
Systemic metabolic alterations and their relationship to neuropsychiatric symptomatology PAIS, including long COVID, as well as CFS and IMD, share the characteristic of systemic metabolic disturbances, which may be a sign of underlying multi-organ inflammation and exhaustion [31], and consequently may contribute to neuropsychiatric symptomatology, as many metabolites can cross the bloodbrain barrier (BBB) [30, 58] (e.g., short chain fatty acids (SCFAs) derived from the gut microbiota such as acetate [40], amino acids such as tryptophan [52] and also carnitine/acetylcarnitine can cross the BBB via transporters [59])
Graphic by Clara Turnage/University Marketing and Communications For patients whose insurance wont cover GLP-1 medications, lower-cost compounded versions can seem like an attractive alternative, but the researchers urge caution
Testing may be appropriate if: Weight loss exceeds 1520% Fatigue, hair thinning or neuropathy develops Persistent vomiting or diarrhoea occurs Dietary intake becomes severely restricted You are in a higher-risk group (e.g., premenopausal women, older adults, GLP-1 + metformin users) Monitoring should be personalised rather than automatic
Mini reviews in medicinal chemistry
In future, precise genetic polymorphic screening tests may play a more central role in determining chemotherapeutic treatment regimens for patients